In a groundbreaking development, Elon Musk’s Neuralink received the FDA’s “breakthrough device” designation for its experimental implant aimed at restoring vision, named Blindsight. This designation is given to devices focusing on life-threatening conditions, expediting their development and review process.
Musk highlighted that Blindsight could restore vision even to those who have lost both eyes and their optic nerve. Neuralink, founded in 2016, aims to implant a brain chip interface to help disabled patients move, communicate, and potentially restore vision.
Neuralink is also testing another implant to enable paralyzed patients to control digital devices through thoughts alone, benefiting those with spinal cord injuries. The trial is set to enroll three patients and may take several years to complete.
Earlier this year, Neuralink successfully implanted the device in a patient, allowing them to play video games and design 3D objects. This innovative technology marks a significant step forward in restoring lost functionalities for individuals with disabilities.
[ad_2]
Source link
